The label for the depression drug Cymbalta adequately warned of the risk of suicidal thoughts and other withdrawal symptoms even though clinical trials indicated a much more substantial incidence of those symptoms, the Southern District of New York held Nov. 7 (McDowell v. Eli Lilly & Co., 2014 BL 315511, S.D.N.Y., 1:13-cv-03786-RWS, 11/7/14).
Judge Robert W. Sweet of the U.S. District Court for the Southern District of New York granted summary judgment for Eli Lilly and Co., the manufacturer of the drug, in a product liability suit.
The court rejected Jesse McDowell’s claims that Cymbalta’s labels were ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.